"Moderna's Enhanced Covid Vaccine Demonstrates Superior Immune Response in Trial"

Moderna's new version of its Covid vaccine has shown a stronger immune response against the virus than its current shot in a late-stage trial, potentially offering a longer shelf life and easier storage. The new shot is designed to last longer when refrigerated and is a critical component of Moderna's combination vaccine targeting Covid and the flu. The phase three trial showed higher immune response against omicron subvariants and the original strain of the virus, particularly in patients over 65. The company plans to present detailed analysis at an upcoming event and is also working on developing shots against the flu, cancer, and other diseases.